Sudeep Pharma Limited

What to Watch

• MarginsOperating margin compressed from ~35.7% to ~32.2% in FY26 (consolidated). Watch input costs and pricing in the next two results.
• Cash FlowOperating cash flow was only 0.4× reported net profit in FY26 (consolidated), a divergence worth watching for receivables or inventory build-up.
• ValuationThe shares trade at 66× trailing earnings; the multiple assumes sustained high growth and is sensitive to any slowdown.
• HistoryShort public market track record with limited historical filing cycles.